KYMR vs NRIX
KYMR: Kymera Therapeutics is a pioneer in targeted protein degradation, developing oral small-molecule drugs that mimic the efficacy of injectable biologics for inflammatory diseases. NRIX: Clinical-stage biotech pioneering AI-powered targeted protein degradation medicines for cancer and autoimmune diseases, with Phase 2 lead candidate bexobrutideg in CLL and partnerships spanning Roche, Gilead, and Sanofi.
Side-by-side fundamentals
| Metric | KYMR | NRIX | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $110.34 | $23.60 | |
| Market cap as of 2026-07-23 | $9.1B | $2.4B | |
| PEG as of 2026-07-23 | -2.09 | -0.21 | KYMR lower |
| Net margin as of 2026-07-23 | -612.0% | -928.4% | KYMR higher |
| Operating margin as of 2026-07-23 | -697.7% | -982.4% | KYMR higher |
| ROE as of 2026-07-23 | -25.0% | -76.1% | KYMR higher |
| ROA as of 2026-07-23 | -22.3% | -57.3% | KYMR higher |
| Debt / equity as of 2026-07-23 | 0.00 | 0.00 | NRIX lower |
| Revenue growth (YoY) as of 2026-07-23 | -12.6% | -58.4% | KYMR higher |
| Revenue CAGR (3y) SEC XBRL | -5.7% | +29.5% | NRIX higher |
| Dividend streak (yrs) SEC XBRL | n/a | 0 | |
| Beta as of 2026-07-23 | 1.94 | 1.77 | |
| 1-year return as of 2026-07-22 close | +151.2% | +108.7% | KYMR higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.